MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Amgen Inc

Abierto

SectorSanidad

279.3 -0.25

Resumen

Variación precio

24h

Actual

Mínimo

276.26

Máximo

281.57

Métricas clave

By Trading Economics

Ingresos

-2.2B

627M

Ventas

586M

9.1B

P/B

Media del Sector

36.153

57.333

BPA

5.31

Rentabilidad por dividendo

3.43

Margen de beneficios

6.901

Empleados

28,000

EBITDA

-517M

2.9B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+16.62% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

3.43%

2.63%

Próximas Ganancias

1 may 2025

Fecha Próximo Dividendo

6 jun 2025

Próxima Fecha de Ex Dividendo

16 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-6B

147B

Apertura anterior

279.55

Cierre anterior

279.3

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

Amgen Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

4 feb 2025, 21:29 UTC

Ganancias

Amgen 4Q Sales Up 11% as Ten Products Post Double-Digit Gains

30 oct 2024, 20:18 UTC

Ganancias

Amgen Posts Higher 3Q Sales on Strong Demand

10 abr 2025, 05:00 UTC

Ganancias

Amgen Is Getting Into the Obesity Drug Business. Buy the Stock Before It Becomes the Next Winner. -- Barrons.com

28 feb 2025, 12:00 UTC

Principales Noticias

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

4 feb 2025, 21:02 UTC

Ganancias

Amgen 4Q SAles Included $1.2 B of Sales From Rare Disease Products >AMGN

4 feb 2025, 21:01 UTC

Ganancias

Amgen 4Q Worldwide Neulasta Sales $98M >AMGN

4 feb 2025, 21:01 UTC

Ganancias

Amgen 4Q Worldwide Enbrel Sales $1.01B >AMGN

4 feb 2025, 21:01 UTC

Ganancias

Amgen 4Q Worldwide Prolia Sales $1.17B >AMGN

4 feb 2025, 21:01 UTC

Ganancias

Amgen Sees FY Rev $34.3B-$35.7B >AMGN

4 feb 2025, 21:01 UTC

Ganancias

Amgen 4Q Adj EPS $5.31 >AMGN

4 feb 2025, 21:01 UTC

Ganancias

Amgen 4Q Worldwide XGEVA Sales $561M >AMGN

4 feb 2025, 21:01 UTC

Ganancias

Amgen Sees FY EPS $10.89-EPS $12.14 >AMGN

4 feb 2025, 21:01 UTC

Ganancias

Amgen Sees FY Adj EPS $20.00-Adj EPS $21.20 >AMGN

4 feb 2025, 21:01 UTC

Ganancias

Amgen 4Q Rev $9.1B >AMGN

4 feb 2025, 21:01 UTC

Ganancias

Amgen 4Q EPS $1.16 >AMGN

4 feb 2025, 21:01 UTC

Ganancias

Amgen 4Q Net $627M >AMGN

28 ene 2025, 10:30 UTC

Principales Noticias

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

27 dic 2024, 07:00 UTC

Ganancias

3 Healthcare Stocks to Buy for a 2025 Rebound -- Barrons.com

23 dic 2024, 15:04 UTC

Principales Noticias

Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark. -- Barrons.com

13 dic 2024, 14:53 UTC

Principales Noticias

Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling. -- Barrons.com

30 nov 2024, 12:00 UTC

Principales Noticias

Eli Lilly and Novo Nordisk's Obesity Moat Just Got Stronger -- Heard on the Street -- WSJ

26 nov 2024, 12:34 UTC

Principales Noticias

Amgen Drug Cut Weight in Closely Watched Study -- WSJ

4 nov 2024, 12:00 UTC

Principales Noticias

Big Pharma's Obesity Bonanza Faces New Tests -- Heard on the Street -- WSJ

30 oct 2024, 20:02 UTC

Ganancias

Amgen 3Q Sales From Rare Disease Products $1.2B >AMGN

30 oct 2024, 20:02 UTC

Ganancias

Amgen CEO: Strong Growth in Sales, Earnings in 3Q Reflects Momentum Being Built Throughout Business>AMGN

30 oct 2024, 20:02 UTC

Ganancias

Amgen: 2024 Buybacks Not to Exceed $500M>AMGN

30 oct 2024, 20:02 UTC

Ganancias

Amgen 3Q Worldwide XGEVA Sales $541M >AMGN

30 oct 2024, 20:02 UTC

Ganancias

Amgen 3Q Worldwide Prolia Sales $1.05B >AMGN

30 oct 2024, 20:01 UTC

Ganancias

Amgen 3Q Worldwide Enbrel Sales $825M >AMGN

30 oct 2024, 20:01 UTC

Ganancias

Amgen 3Q Worldwide XGEVA Sales $541M >AMGN

Comparación entre iguales

Cambio de precio

Amgen Inc previsión

Precio Objetivo

By TipRanks

16.62% repunte

Estimación a 12 Meses

Media 326.36 USD  16.62%

Máximo 389 USD

Mínimo 280 USD

De acuerdo con 18 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Amgen Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

18 ratings

9

Comprar

8

Mantener

1

Vender

Puntuación técnica

By Trading Central

278.68 / 295.18Soporte y Resistencia

Corto Plazo

Weak Bearish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.